1Guerre- Millo M et al. Peroxisome proliferator - activated receptor alpha activators improve insulin sensitivity and reduce adiposity.J Biol Chem 2000;275:16638- 16642.
2Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth - muscle cells is inhibited by PPAR - α but not by PPAR - γactivators. Nature 1998 ;393: 790 - 793.
3Marx N, Duez H, Fruchart J. C, et al. Peroxisome proliferator -activated receptors and atherogenesis regulators of gene expression in vascular cells, Circ Res 2004;94:1168- 1179.
4Walus B. I, Sieradzki J, Rostworowski W, et al. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J of Clin Invest 2000; 30: 871 - 878.
5Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo- controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study(DAIS). Am J Kidney Dis 2005 ;45:485 - 493.
6Noguhi Y, Tatsuno I, Suyama K, et al. Effects of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. J atheroscler thromb 2004; 11: 335 - 340.
7Feher M. D; Hepburn A. L; Hogarth M. B, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuicaemia and gout……Rheumatology 2003 ;42,321 - 325.
8Vera T, Taylor M, Bohman Q, et al. Fenofibrate prevents the development of angiotensin Ⅱ - dependent hypertension in mice. Hypertension 2005 ;45:730 - 735.
9Ohira H, Sato Y, Ueno T, et al. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97:2147-2149.
10The FIELD Study Investigators. The need for a large- scale trial of fibrate theapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)study Cardiovascular Diabetology 2004; 3: 9 - 20.
